AcceleDev Chemical LLC Opens Advanced 5,000-Sq.-Ft. R&D/GMP Facility in Cranbury, NJ

CRANBURY, NJ / ACCESSWIRE / July 11, 2024 / AcceleDev Chemical LLC, a leader in custom synthesis services, has announced the inauguration of its new 5,000-square-foot R&D and GMP production site at 1 Duncan Drive, Cranbury, New Jersey. This expansion aligns with the company's mission to provide innovative chemistry solutions and aid in new drug development.

Founded in 2003 by Charlie Lewis, AcceleDev has consistently delivered cutting-edge synthesis solutions for the pharmaceutical sector. The new facility will significantly bolster the company's R&D and production capabilities, focusing on early development active ingredients and intermediates for the U.S. market.

Charlie Lewis, Founder and Managing Director, emphasized the facility's role in enhancing their innovation and chemistry excellence. Dr. Dave Tschaen, Chief Scientific Officer, noted that the lab, outfitted with GMP suites and advanced technology, will enhance both their technical capabilities and adherence to rigorous quality standards.

The move to a larger lab was driven by the need to expand AcceleDev's R&D and small-scale production capacities in the USA. With three process development rooms, an analytical lab, and two isolated GMP suites, the facility is set to attract clients and reinforce confidence in the company's quality commitment.

AcceleDev offers extensive services, from API process design to commercial scale production. The company's global team includes 70 chemists, with operations in Shanghai, New Jersey, Jiangyin, and Dalian. This new Cranbury lab signifies a strategic step in supporting pharmaceutical innovations.